Optic IconOptic Logo
|
SearchCollectionsBenchmarks

nemtabrutinib

1 product

6 abstracts

Abstract
BELLWAVE-011: Phase 3 randomized trial of nemtabrutinib versus ibrutinib or acalabrutinib in untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
Org: Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom, Haematology Unit, Bnai Zion Medical Center, Haifa, Israel, Department of Hematology & BMT, Chaim Sheba Medical Center, Tel Aviv, Israel, Summit Cancer Center, Spok, WA, Hadassah Medical Center, Jerusalem, Israel,
Abstract
BELLWAVE-010: A phase 3 study of nemtabrutinib plus venetoclax versus venetoclax plus rituximab (VR) in previously treated patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Org: Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele,
Abstract
Efficacy outcomes of treatments for double exposed chronic lymphocytic leukemia/small lymphocytic lymphoma: A systematic literature review.
Org: Clinical and Administrative Pharmacy, Health Economics and Health Services Research,
Abstract
A phase IIA clinical trial to evaluate a reversible Bruton’s tyrosine kinase inhibitor (BTKi) HBW-3220 capsules in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).
Org: Chengdu Hyperway Pharmaceuticals, Chengdu, China,
Abstract
BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.
Org: Istanbul Medipol University Medical Faculty, International School of Medicine, Merck & Co., Inc., Rahway, NJ, Maria Sklodowska-Curie National Institute of Oncology,
Abstract
BELLWAVE-003: A phase 2 dose escalation, confirmation, and cohort expansion study of nemtabrutinib in hematologic malignancies.
Org: Hospital Paulistano and Instituto Américas, Tom Baker Cancer Centre, Ankara University School of Medicine, MSC National Research Institute of Oncology, Kraków, Poland, Institut Català d'Oncologia Hospitalet,
Product
Nemtabrutinib